ENTYVIO
GrowthmAbBLAINTRAVENOUSINJECTABLE
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
5/8 — Partial
ENTYVIO by Takeda is α4β7 integrin and blocks the interaction of α4β7 integrin with mucosal addressin cell adhesion molecule-1 (madcam-1) and inhibits the migration of memory t-lymphocytes across the endothelium into inflamed gastrointestinal parenchymal tissue. First approved in 2024.
Drug data last refreshed 16h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENTYVIO (vedolizumab) is a monoclonal antibody that selectively blocks α4β7 integrin, preventing memory T-lymphocytes from migrating into inflamed gastrointestinal tissue. It is indicated for ulcerative colitis and Crohn's disease, two chronic inflammatory bowel diseases where gut-specific immune dysregulation drives disease pathology. The gut-selective mechanism of action minimizes systemic immunosuppression compared to pan-integrin antagonists.
$0.1BPart D
GrowthEarly-stage growth phase with modest current Medicare spending; Takeda is likely expanding commercial infrastructure and field teams to drive adoption.
Mechanism of Action
α4β7 integrin and blocks the interaction of α4β7 integrin with mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and inhibits the migration of memory T-lymphocytes across the endothelium into inflamed gastrointestinal parenchymal tissue. Vedolizumab does not bind to or inhibit function of the…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
Study to Investigate Comparative Pharmacokinetics, Safety, Immunogenicity and Tolerability Between AVT80 and Entyvio
Started Feb 2025
385 enrolled
Healthy Male and Female Subjects
Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio
Started Sep 2024
301 enrolled
Ulcerative Colitis
Efficacy, Safety and Immunogenicity of the Proposed Biosimilar Vedolizumab PB016 in Comparison With Entyvio®
Started Jul 2023
750 enrolled
Ulcerative Colitis
ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily Practice
Started Sep 2020
0Crohn Disease
Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)
Started Jan 2017
19 enrolled
ULCERATIVE COLITIS
Worked on ENTYVIO at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.